Dr Neal Shore emphasizes the importance of accurate staging of prostate cancer and how PYLARIFY® (piflufolastat F 18) can improve treatment decision-making in patients with prostate cancer. Read More ›
Dr Neal Shore highlights example patient populations that may benefit from improved staging through the use of PYLARIFY® (piflufolastat F 18), a prostate-specific membrane antigen (PSMA)-targeted PET/CT agent. Read More ›
Dr Neal Shore discusses the importance of PSMA PET imaging across a range of PSA values and how PYLARIFY® (piflufolastat F 18) will affect imaging of patients with oligometastatic prostate cancer. Read More ›
Dr Neal Shore elaborates on the ability of PYLARIFY® (piflufolastat F 18) to detect metastases and the practical aspects of next-generation imaging. Read More ›
Dr Neal Shore discusses the rationale of prostate-specific membrane antigen (PSMA) PET/CT to guide prostate cancer treatment. Read More ›
Dr Neal Shore introduces the current global landscape of various imaging modalities for prostate cancer, including a new prostate-specific membrane antigen (PSMA)-targeted PET/CT agent, PYLARIFY® (piflufolastat F 18). Read More ›
An Interview with Kelly Grosklags, LICSW, BCD, FAAGC Read More ›
Dr Ezra Cohen of UC San Diego, La Jolla, CA; Dr Mary Fidler of Rush University Medical Center, Chicago, IL; and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, explain the benefits of testing for TRK fusion–positive tumors early for improved clinical outcomes. Read More ›
Dr Ezra Cohen of UC San Diego, La Jolla, CA, and Dr Mary Fidler of Rush University Medical Center, Chicago, IL, recount their clinical experiences and the journeys of patients treated with TRK inhibitors for thyroid cancer. Read More ›
Dr Mary Fidler of Rush University Medical Center, Chicago, IL, and Dr Arturo Loaiza-Bonilla of the Comprehensive Care and Research Center, Philadelphia, PA, describe their practical experiences with TRK inhibitors in patients with lung cancer and colorectal cancer. Read More ›